<DOC>
	<DOCNO>NCT01998542</DOCNO>
	<brief_summary>The purpose study determine safety tolerability personalize anti-cancer vaccine AlloVax ( TM ) Subjects confirmed recurrent metastatic squamous cell carcinoma head neck ( SCCHN ) treat surgery , chemotherapy radiation . AlloVax ( TM ) personalize anti-cancer vaccine combine Chaperone Rich Cell Lysate ( CRCL ) source tumor antigen prepare patient 's tumor AlloStim ( TM ) adjuvant . The combination CRCL AlloStim ( TM ) design provide key component necessary develop tumor-specific immunity create inflammatory environment necessary overcome HNC immunosuppressive environment , break tumor immune tolerance , provision specific HNC antigens generation specific adaptive anti-tumor response .</brief_summary>
	<brief_title>Safety Tolerability Study AlloVax ( TM ) Patients With Metastatic Recurrent Cancer Head Neck</brief_title>
	<detailed_description>This randomize , double blind , placebo control study . The subject investigator blind treatment arm . All accrued subject undergo tumor harvest procedure . The tumor sample process personalized Chaperone Rich Cell Lysate ( CRCL ) vaccine . Subjects assign 3:1 ratio AlloVax ( TM ) ( CRCL AlloStim ( TM ) ) placebo control arm . Both arm receive best supportive care . Arm 1 receive AlloVax ( TM ) ( intradermal injection AlloSim ( TM ) follow immediately intradermal injection CRCL ) weekly 3 week follow intravenous infusion AlloStim ( TM ) week 4 ( cycle 1 ) . Arm 2 receive AlloVax ( TM ) placebo weekly 3 week follow intravenous infusion AlloStim ( TM ) placebo week 4 ( cycle 1 ) . This experimental treatment schedule continue 4 cycle .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>1 . Adult male female patient age 18 70 year old , inclusive , screen visit . 2 . Patients histopatholologically cytologically confirm diagnosis recurrent metastatic squamous cell carcinoma head neck ( SCCHN ) incurable surgery , chemotherapy radiation . No nasopharyngeal primary . 3 . Patients must tumor safely accessable surgical excision result minimum 0.5 g tumor sample CRCL processing . 4 . Patients must measurable disease accord revise RECIST v.1.1 guideline least one lesion deem safely accessible serial biopsy . 5 . ECOG ≤2 . 6 . The result screen test criterion : 6.1 Adequate organ function include : A . Marrow : WBC &gt; 3000/mm3 Platelets &gt; 100,000/mm3 . Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) B. Hepatic : Serum Total bilirubin &lt; 2 x ULN mg/dL , ALT ( SGPT ) / AST ( SGOT ) ≤3 x upper limit normal ( ULN ) . C. Renal : Serum creatinine ( SCR ) &lt; 2.0 x ULN , Creatinine clearance ( CCR ) &gt; 30 mL/min . 6.2 All patient prestudy echocardiogram without significant abnormality Ejection fraction &gt; 50 % . 6.3 All patient must screen negative HIV1 , HIV2 , HTLVI , HTLVII , HBV , HCV RPR ( syphilis ) . 6.4 Women childbearing potential must negative urine serum pregnancy test result within 72 hour prior start study drug administration . 7 . All patient child produce potential must agree use contraception avoidance pregnancy measure enrol study receive experimental product . 8 . Patients must ability understand study , inherent risk , side effect potential benefit able give write informed consent participate . 1 . Clinical evidence radiological evidence nasopharyngeal primary . 2 . Clinical evidence radiological evidence brain metastasis . 3 . History severe hypersensitivity monoclonal antibody drug contraindication study drug . 4 . Concomitant active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) . 5 . Prior experimental therapy cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) . 6 . Clinical requirement systemic steroid current immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 1 month study entry . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , require parenteral antibiotic , symptomatic congestive heart failure , severe myocardial insufficiency , cardiac arrhythmia 8 . All infection must resolve patient must remain febrile seven day prior place study . 9 . History blood transfusion reaction . 10 . Psychiatric addictive disorder condition , opinion investigator , would preclude study participation . 11 . Pregnant breast feeding . The patient discontinuation participation study : 1 . Less 12 dos CRCL able produce 2 . Tumor sample CRCL processing contain less 80 % tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>tumor vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>personalize anti-cancer vaccine</keyword>
</DOC>